Aditya Birla Sunlife Life Pharma & Healthcare Growth Direct Plan
SIP amount
Min. ₹100
Lumpsum amount
Min. ₹1,000

Aditya Birla Sunlife Life Pharma & Healthcare Growth Direct Plan

NAV
₹33.9900
-0.85%
(20 Dec)
AUM
882 Cr
TER
0.92%
Risk
Very High Risk
Insights
Net Asset Value (NAV) is above its 200 days moving average
In beta. Send feedback here.
Compare with other fund
1Y
+38.7%
+34.0%
+33.2%
+32.7%
+20.7%
3Y
+21.4%
+36.3%
+35.8%
+37.7%
+35.8%
5Y
+26.2%
+29.7%
+31.7%
+26.2%
NA
ALL
+25.3%
+17.8%
+18.1%
+12.5%
+28.6%
VOL
15.6%
19.6%
18.1%
20.3%
22.7%
TER
0.9%
0.8%
1.2%
0.7%
0.5%
AUM
₹882 Cr
₹1,345 Cr
₹6,779 Cr
₹4,686 Cr
₹5,456 Cr
INFO
1.62
0.91
1.00
0.62
1.26
Past performance
Past performance is no guarantee of future returns.
Had you invested
Over the last
1Y
3Y
ALL
Your returns would have been
Aditya Birla Sunlife Life Pharma & Healthcare (G)
₹1,00,00,00,000
14.0%
Fixed deposit
₹40,00,00,000
6.0%
Bank savings
₹40,00,00,000
3.0%
See fund holdings as of 31st Oct
Top holdings
Sun Pharmaceuticals Industries Ltd
14.4%
Cipla Ltd
8.8%
Torrent Pharmaceuticals Ltd
7.1%
Clearing Corporation Of India Limited
6.4%
Apollo Hospitals Enterprise Ltd
5.9%
Aurobindo Pharma Ltd
5.4%
Fortis Healthcare Ltd
5.2%
Ajanta Pharma Ltd
4.5%
Lupin Ltd
4.1%
Ipca Laboratories Ltd
4.0%
Top industry exposure
Healthcare
91.4%
Financial Services
1.4%
Basic Materials
0.9%
Other information
Minimum SIP
₹100
Minimum lumpsum
₹1,000
Additional lumpsum
₹1,000
Portfolio turnover
21%
Lock-in period
-
Exit load
• 1% for redemption within 30 days
Fund objective
The scheme provides long term capital appreciation by investing in equity/equity related instruments of the companies in the Pharmaceuticals, Healthcare and Allied sectors in India. The Scheme does not guarantee/indicate any returns. There can be no assurance that the schemes’ objectives will be achieved.
Fund manager(s)
Dhaval Shah
Dhaval Joshi

FAQs